C-MAS9alternative splicing modulation, CLK/DYRK inhibition, Wnt pathway modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Biosplice (was Samumed) alternative splicing modulation, CLK/DYRK inhibition, Wnt pathway modulation
Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Its platform uses small molecules targeting CLK/DYRK family kinases to modulate disease-selective RNA splice-site selection and related pathways. The company’s clinical pipeline is focused on osteoarthritis and oncology, with earlier programs in neurology, diabetes, and other areas of unmet medical need.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Biosplice (was Samumed) — Near-term readout · Lower middle. Derived deterministically from 6 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic